Nathaniel Ross Liddy

USPTO Granted Patents = 11 (Patent Applications = 14)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 14)

Average Co-Inventor Count = 4.2

ph-index = 4

Forward Citations = 54(Granted Patents)

Location History:

Oxon, GB (2012)
Oxfordshire, GB (2015)
Abingdon, GB (2012 - 2024)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2012-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12195534 - Binding molecules (2025-01-14),

2. 12134647 - Binding molecules (2024-11-05),

3. 12018062 - T cell receptors (2024-06-25),

4. 11739442 - TCR libraries (2023-08-29),

5. 11718657 - T cell receptors (2023-08-08),

6. 11505590 - T cell receptors (2022-11-22),

7. 11427624 - T cell receptors (2022-08-30),

8. 11124556 - TCR libraries (2021-09-21),

9. 9068178 - Nucleic acid molecules encoding non-naturally occurring T cell receptors and cells thereof (2015-06-30),

10. 8283446 - T cell receptor mutants (2012-10-09),

11. 8217144 - High affinity Melan-A T cell receptors (2012-07-10),

Title: Nathaniel Ross Liddy: Innovator in Binding Molecules

Introduction

Nathaniel Ross Liddy is a prominent inventor based in Abingdon, GB. He has made significant contributions to the field of biotechnology, particularly in the development of binding molecules that target specific peptide-HLA complexes. With a total of 11 patents to his name, Liddy is recognized for his innovative approaches to treating malignant diseases.

Latest Patents

Liddy's latest patents focus on binding molecules that comprise T cell receptor (TCR) variable domains. One of his inventions relates to binding molecules that can bind to a PIWIL1 peptide-HLA complex, which has potential applications in the treatment of malignant diseases. Another notable patent involves binding molecules that target a PRAME peptide-HLA complex, specifically binding to the sequence PYLGQMINL in complex with HLA-A24. These advancements highlight Liddy's commitment to addressing critical health challenges through innovative solutions.

Career Highlights

Throughout his career, Nathaniel Ross Liddy has worked with leading companies in the biotechnology sector, including Immunocore Limited and Adaptimmune Limited. His work has been instrumental in advancing the understanding and application of T cell receptor technology in therapeutic contexts. Liddy's expertise and innovative mindset have positioned him as a key figure in the field.

Collaborations

Liddy has collaborated with notable professionals in the industry, including Bent Karsten Jakobsen and Tara Mahon. These partnerships have further enriched his research and development efforts, contributing to the success of his inventions.

Conclusion

Nathaniel Ross Liddy is a distinguished inventor whose work in binding molecules has the potential to revolutionize treatments for malignant diseases. His innovative patents and collaborations reflect his dedication to advancing biotechnology.

This text is generated by artificial intelligence and may not be accurate.